TABLE 1.

PATIENT CHARACTERISTICS

	GOG 120 (n=176)	GOG 165 (n=159)	Total (n=335)
Characteristic	No. (%)	No. (%)	No. (%)
Age (years); Median (Range)	47 (25–80)	48 (27–78)	47 (20–80)
≤ 40	56 (31.8)	34 (21.4)	90 (26.9)
41–50	50 (28.4)	52 (32.7)	102 (30.5)
51–60	34 (19.3)	35 (22.0)	69 (20.6)
> 60	36 (20.5)	38 (23.9)	74 (22.1)
Race
Caucasian	101 (57.4)	98 (61.6)	199 (59.4)
African American	45 (25.6)	29 (18.2)	74 (22.1)
Hispanic	24 (13.6)	22 (13.8)	46 (13.7)
Asian/Pacific Island	5 (2.8)	10 (6.3)	15 (4.5)
Other	1 (0.6)	0 (0.0)	1 (0.3)
GOG Performance Status
0	104 (59.1)	129 (81.1)	233 (69.6)
1	63 (35.8)	26 (16.4)	89 (26.6)
2	9 (5.1)	4 (2.5)	13 (3.9)
Histology
Squamous	157 (89.2)	135 (84.9)	292 (87.2)
Adenosquamous	13 (7.4)	10 (6.3)	23 (6.9)
Adenocarcinoma	5 (2.8)	10 (6.3)	15 (4.5)
Other	1 (0.6)	4 (2.5)	5 (1.5)
Tumor Grade
1	15 (8.5)	12 (7.6)	27 (8.1)
2	116 (65.9)	87 (54.7)	203 (60.6)
3	45 (25.6)	60 (37.7)	105 (31.3)
FIGO Stage
IIB	102 (58.0)	106 (66.7)	208 (62.1)
IIIA	3 (1.7)	0 (0.0)	3 (0.9)
IIIB	67 (38.1)	47 (29.6)	114 (34.0)
IVA	4 (2.3)	6 (3.8)	10 (3.0)
Surgical Staging
Yes	176 (100.0)	29 (18.2)	205 (61.2)
No	0 (0.0)	130 (81.8)	130 (38.8)
Tumor Size (cm); Median (Range)	6.0 (2.0–12.0)	6.0 (2.0–12.0)	6.0 (2.0–12.0)
≤ 4.0	25 (14.2)	33 (20.8)	58 (17.3)
4.1–5.0	22 (12.5)	32 (20.1)	54 (16.1)
5.1–6.0	49 (27.8)	34 (21.4)	83 (24.8)
6.1–7.0	27 (15.3)	26 (16.4)	53 (15.8)
7.1–8.0	30 (17.1)	24 (15.1)	54 (16.1)
> 8.0	23 (13.1)	10 (6.3)	33 (9.9)